pomalidomide has been researched along with Crow-Fukase Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buadi, F; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, R; Gonsalves, W; Hayman, S; Hobbs, M; Hwa, Y; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Muchtar, E; Rajkumar, SV; Siddiqui, M; Vaxman, I; Warsame, R | 1 |
| Blum, S; Borgeat Kaeser, A; Cairoli, A; Grandoni, F; Ribi, C; Stalder, G | 1 |
2 other study(ies) available for pomalidomide and Crow-Fukase Syndrome
| Article | Year |
|---|---|
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; POEMS Syndrome; Thalidomide | 2023 |
Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs.
Topics: Aged; Biomarkers; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Magnetic Resonance Imaging; POEMS Syndrome; Thalidomide; Treatment Outcome | 2019 |